Paradoxical Roles of Tumour Necrosis Factor-alpha in Prostate Cancer Biology

Overview

Journal Prostate Cancer

Publisher Wiley

Date 2013 Jan 18

PMID 23326670

Citations 30

Authors

Brian W C Tse

Kieran F Scott

Pamela J Russell

Affiliations

Soon will be listed here.

Abstract

Tumour necrosis factor (TNF) is a pleiotropic cytokine with dual roles in cancer biology including prostate cancer (PCa). On the one hand, there is evidence that it stimulates tumour angiogenesis, is involved in the initiation of PCa from an androgen-dependent to a castrate resistant state, plays a role in epithelial to mesenchymal plasticity, and may contribute to the aberrant regulation of eicosanoid pathways. On the other hand, TNF has also been reported to inhibit neovascularisation, induce apoptosis of PCa cells, and stimulate antitumour immunity. Much of the confusion surrounding its seemingly paradoxical roles in cancer biology stems from the dependence of its effects on the biological model within which TNF is investigated. This paper will address some of these issues and also discuss the therapeutic implications.

Citing Articles

Periprostatic Adipose Tissue as a Contributor to Prostate Cancer Pathogenesis: A Narrative Review.

Drewa J, Lazar-Juszczak K, Adamowicz J, Juszczak K Cancers (Basel). 2025; 17(3).

PMID: 39941741 PMC: 11816168. DOI: 10.3390/cancers17030372.

Salivary miRNAs and cytokines associated with diagnosis and prognosis of oral squamous cell carcinoma.

Qin Y, Dong X, Li B Front Cell Dev Biol. 2025; 13:1531016.

PMID: 39911325 PMC: 11794800. DOI: 10.3389/fcell.2025.1531016.

Polygenic anti-cancer activity of in prostate cancer induced animal model.

Alabi G, Elekofehinti O, Sanni D, Ashaolu J, Oluwatuyi A Toxicol Rep. 2024; 13:101774.

PMID: 39554609 PMC: 11567122. DOI: 10.1016/j.toxrep.2024.101774.

Impact of loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Slootbeek P, Luna-Velez M, Prive B, van der Doelen M, Kloots I, Pamidimarri Naga S Theranostics. 2024; 14(12):4555-4569.

PMID: 39239510 PMC: 11373632. DOI: 10.7150/thno.96322.

Regulatory and effector T cell subsets in tumor-draining lymph nodes of patients with squamous cell carcinoma of head and neck.

Norouzian M, Mehdipour F, Ashraf M, Khademi B, Ghaderi A BMC Immunol. 2022; 23(1):56.

PMID: 36376825 PMC: 9664675. DOI: 10.1186/s12865-022-00530-3.

References

Nunez C, Cansino J, Bethencourt F, Perez-Utrilla M, Fraile B, Martinez-Onsurbe P . TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology. 2008; 53(2):166-76. DOI: 10.1111/j.1365-2559.2008.03092.x. View

Locke J, Guns E, Lubik A, Adomat H, Hendy S, Wood C . Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008; 68(15):6407-15. DOI: 10.1158/0008-5472.CAN-07-5997. View

Nakashima J, Tachibana M, Ueno M, Baba S, Tazaki H . Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res. 1995; 55(21):4881-5. View

Ludwig J, Weinstein J . Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005; 5(11):845-56. DOI: 10.1038/nrc1739. View

Kuhweide R, Van Damme J, Ceuppens J . Tumor necrosis factor-alpha and interleukin 6 synergistically induce T cell growth. Eur J Immunol. 1990; 20(5):1019-25. DOI: 10.1002/eji.1830200511. View

Ohshima H, Tatemichi M, Sawa T . Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys. 2003; 417(1):3-11. DOI: 10.1016/s0003-9861(03)00283-2. View

De Miguel M, Royuela M, Bethencourt F, Santamaria L, Fraile B, Paniagua R . Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate. Cytokine. 2000; 12(5):535-8. DOI: 10.1006/cyto.1999.0585. View

Chow M, Moller A, Smyth M . Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012; 22(1):23-32. DOI: 10.1016/j.semcancer.2011.12.004. View

Wang D, Montgomery R, Schmidt L, Mostaghel E, Huang H, Nelson P . Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res. 2009; 69(24):9448-56. PMC: 2795008. DOI: 10.1158/0008-5472.CAN-09-1903. View

10.

Konig J, Senge T, Allhoff E, Konig W . Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004; 58(2):121-9. DOI: 10.1002/pros.10317. View

11.

Chung T, Mauceri H, Hallahan D, Yu J, Chung S, Grdina W . Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1999; 5(6):344-9. View

12.

CARSWELL E, Old L, Kassel R, Green S, Fiore N, Williamson B . An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975; 72(9):3666-70. PMC: 433057. DOI: 10.1073/pnas.72.9.3666. View

13.

Smyth M, Kelly J, Baxter A, Korner H, Sedgwick J . An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med. 1998; 188(9):1611-9. PMC: 2212521. DOI: 10.1084/jem.188.9.1611. View

14.

Diaz Jr L, Messersmith W, Sokoll L, Sinibaldi V, Moore S, Carducci M . TNF-blockade in patients with advanced hormone refractory prostate cancer. Invest New Drugs. 2009; 29(1):192-4. PMC: 3272825. DOI: 10.1007/s10637-009-9346-1. View

15.

Thalmann G, Anezinis P, Chang S, Zhau H, Kim E, Hopwood V . Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994; 54(10):2577-81. View

16.

Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A . Selective targeted delivery of TNFalpha to tumor blood vessels. Blood. 2003; 102(13):4384-92. DOI: 10.1182/blood-2003-04-1039. View

17.

Funk C . Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001; 294(5548):1871-5. DOI: 10.1126/science.294.5548.1871. View

18.

Subbarayan V, Sabichi A, Llansa N, Lippman S, Menter D . Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res. 2001; 61(6):2720-6. View

19.

Hughes-Fulford M, Li C, Boonyaratanakornkit J, Sayyah S . Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res. 2006; 66(3):1427-33. DOI: 10.1158/0008-5472.CAN-05-0914. View

20.

Sella A, Aggarwal B, Kilbourn R, Bui C, Zukiwski A, Logothetis C . Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. Cancer Biother. 1995; 10(3):225-35. DOI: 10.1089/cbr.1995.10.225. View